Your shopping cart is currently empty

Bremelanotide Acetate (PT-141 Acetate) is an agonist of melanocortin receptor (MCR) .

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | $46 | In Stock | In Stock | |
| 25 mg | $83 | In Stock | In Stock | |
| 50 mg | $139 | In Stock | In Stock | |
| 100 mg | $207 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $65 | In Stock | In Stock |
| Description | Bremelanotide Acetate (PT-141 Acetate) is an agonist of melanocortin receptor (MCR) . |
| In vivo | Treatment with Bremelanotide?(100 or 200 μg/kg) significantly increased proceptive solicitations in females primed with E+Por E alone (E+O) in bilevel chambers[1] |
| Animal Research | Bremelanotide(PT-141), a cyclic heptapeptide melanocortin analogue (Palatin Technologies, Cranbury, NJ), was dissolved in saline to obtain doses of 50, 100, and 200 μg/kg/ml, and injected s.c. 5 min before each behavioral test. An equal volume of saline was administered to control animals[1]. |
| Synonyms | PT-141 Acetate |
| Molecular Weight | 1085.22 |
| Formula | C52H72N14O12 |
| Cas No. | 1607799-13-2 |
| Smiles | CC(O)=O.[H][C@]1(CCCCNC(=O)C[C@H](NC(=O)[C@H](CCCC)NC(C)=O)C(=O)N[C@@H](Cc2cnc[nH]2)C(=O)N[C@]([H])(Cc2ccccc2)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2c[nH]c3ccccc23)C(=O)N1)C(O)=O |
| Relative Density. | no data available |
| Sequence | Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)-OH.CH3CO2H |
| Sequence Short | XDHFRWK |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 122.5 mg/mL (112.88 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (1.84 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.